

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 February 2023 (02.02.2023)



(10) International Publication Number
WO 2023/004461 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) *C07K 16/32* (2006.01)
A61P 35/00 (2006.01) *C07K 14/47* (2006.01)
A61P 35/02 (2006.01) *C07K 14/705* (2006.01)
C07K 16/28 (2006.01) *C07K 14/715* (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/AU2022/050795

(22) International Filing Date:

28 July 2022 (28.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2021902320 28 July 2021 (28.07.2021) AU

(71) Applicant: **PRESCIENT THERAPEUTICS LTD**

[AU/AU]; Level 4, 100 Albert Road, South Melbourne, Vic-
toria 3205 (AU).

(72) Inventors: **YATOMI-CLARKE, Steven L.**; C/O: Pre-

scient Therapeutics Ltd of Level 4, 100 Albert Road, South
Melbourne, Victoria 3205 (AU). **LIM, Rebecca**; C/O: Pre-
scient Therapeutics Ltd of Level 4, 100 Albert Road, South
Melbourne, Victoria 3205 (AU). **DARCY, Philip K.**; C/
O: Prescient Therapeutics Ltd of Level 4, 100 Albert Road,
South Melbourne, Victoria 3205 (AU). **SHELLY, Daniel
A.**; C/O: Prescient Therapeutics Ltd of Level 4, 100 Al-
bert Road, South Melbourne, Victoria 3205 (AU). **SEK,
Kevin**; C/O: Prescient Therapeutics Ltd of Level 4, 100 Al-
bert Road, South Melbourne, Victoria 3205 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins St, Mel-
bourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: UNIVERSAL RECEPTOR IMMUNE CELL THERAPY

(57) Abstract: The present invention relates to methods for universal immune receptor cell based therapies.



WO 2023/004461 A1